<?xml version="1.0" encoding="UTF-8" standalone="yes"?><Rowset rowCount='4'><Row><Action id="419">Factor VIIa agonist</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1002460">PolyTherics Ltd</Company><Country id="GB">UK</Country><Drug id="76707">PEGylated Factor VIIa (TheraPEG, hemophilia), PolyTherics/Pro Bono Bio/Cantab</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="439">Hemophilia</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-01-20 00:00:00</LatestChange><ParentCompany id="1096483">Abzena plc</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2012-05-29 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="142">Hematological disease</TherapyArea></Row><Row><Action id="419">Factor VIIa agonist</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="15303">Cantab Biopharmaceuticals Ltd</Company><Country id="GB">UK</Country><Drug id="76707">PEGylated Factor VIIa (TheraPEG, hemophilia), PolyTherics/Pro Bono Bio/Cantab</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="439">Hemophilia</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-01-20 00:00:00</LatestChange><ParentCompany id="1014955">Celtic Pharmaceutical Holdings LP</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2012-07-20 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="142">Hematological disease</TherapyArea></Row><Row><Action id="419">Factor VIIa agonist</Action><AuthorityGroup>LOCAL_AND_MAJOR</AuthorityGroup><Company id="1068320">Pro Bono Bio</Company><Country id="GB">UK</Country><Drug id="76707">PEGylated Factor VIIa (TheraPEG, hemophilia), PolyTherics/Pro Bono Bio/Cantab</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="439">Hemophilia</Indication><IsActiveCompany>true</IsActiveCompany><LatestChange>2014-01-20 00:00:00</LatestChange><ParentCompany id="1068320">Pro Bono Bio</ParentCompany><Status id="DR">Discovery</Status><StatusDate>2012-03-19 00:00:00</StatusDate><StatusSortCode>6</StatusSortCode><TherapyArea id="142">Hematological disease</TherapyArea></Row><Row><Action id="419">Factor VIIa agonist</Action><AuthorityGroup>OTHER</AuthorityGroup><Company id="15303">Cantab Biopharmaceuticals Ltd</Company><Country id="GB">UK</Country><Drug id="76707">PEGylated Factor VIIa (TheraPEG, hemophilia), PolyTherics/Pro Bono Bio/Cantab</Drug><EntityType>Biological</EntityType><HighestDevStatus id="DR">Discovery</HighestDevStatus><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="439">Hemophilia</Indication><IsActiveCompany>false</IsActiveCompany><LatestChange>2014-01-20 00:00:00</LatestChange><ParentCompany id="1014955">Celtic Pharmaceutical Holdings LP</ParentCompany><Status id="NDR">No Development Reported</Status><StatusDate>2014-01-20 00:00:00</StatusDate><StatusSortCode>2</StatusSortCode><TherapyArea id="142">Hematological disease</TherapyArea></Row></Rowset>